Introduction to a How I Treat series on plasma cell dyscrasias

The treatment paradigms for multiple myeloma and amyloidosis have been transformed by novel therapies and continue to be modified in the face of new immunologic agents. In this How I Treat series on plasma cell dyscrasias edited by Associate Editor Hervé Avet-Loiseau, experts in the field discuss the rapidly changing treatment landscape for multiple myeloma and light-chain amyloidosis. Using illustrative cases, they review the role of autologous transplant, novel combination therapies, and the impact of new immunotherapy approaches to these complex and heterogeneous diseases.